These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

253 related items for PubMed ID: 15911309

  • 1. Design, synthesis, and biological activity of non-basic compounds as factor Xa inhibitors: SAR study of S1 and aryl binding sites.
    Komoriya S, Haginoya N, Kobayashi S, Nagata T, Mochizuki A, Suzuki M, Yoshino T, Horino H, Nagahara T, Suzuki M, Isobe Y, Furugoori T.
    Bioorg Med Chem; 2005 Jun 02; 13(12):3927-54. PubMed ID: 15911309
    [Abstract] [Full Text] [Related]

  • 2. Design, synthesis, and biological activity of novel factor Xa inhibitors: improving metabolic stability by S1 and S4 ligand modification.
    Komoriya S, Kobayashi S, Osanai K, Yoshino T, Nagata T, Haginoya N, Nakamoto Y, Mochizuki A, Nagahara T, Suzuki M, Shimada T, Watanabe K, Isobe Y, Furugoori T.
    Bioorg Med Chem; 2006 Mar 01; 14(5):1309-30. PubMed ID: 16263291
    [Abstract] [Full Text] [Related]

  • 3. Rational design and synthesis of novel, potent bis-phenylamidine carboxylate factor Xa inhibitors.
    Maduskuie TP, McNamara KJ, Ru Y, Knabb RM, Stouten PF.
    J Med Chem; 1998 Jan 01; 41(1):53-62. PubMed ID: 9438022
    [Abstract] [Full Text] [Related]

  • 4. Design, synthesis and biological activity of amidinobicyclic compounds (derivatives of DX-9065a) as factor Xa inhibitors: SAR study of S1 and aryl binding sites.
    Komoriya S, Kanaya N, Nagahara T, Yokoyama A, Inamura K, Yokoyama Y, Katakura S, Hara T.
    Bioorg Med Chem; 2004 May 01; 12(9):2099-114. PubMed ID: 15080912
    [Abstract] [Full Text] [Related]

  • 5. Structure and property based design of factor Xa inhibitors: pyrrolidin-2-ones with biaryl P4 motifs.
    Young RJ, Borthwick AD, Brown D, Burns-Kurtis CL, Campbell M, Chan C, Charbaut M, Chung CW, Convery MA, Kelly HA, Paul King N, Kleanthous S, Mason AM, Pateman AJ, Patikis AN, Pinto IL, Pollard DR, Senger S, Shah GP, Toomey JR, Watson NS, Weston HE.
    Bioorg Med Chem Lett; 2008 Jan 01; 18(1):23-7. PubMed ID: 18054228
    [Abstract] [Full Text] [Related]

  • 6. Design and structure-activity relationships of potent and selective inhibitors of blood coagulation factor Xa.
    Ewing WR, Becker MR, Manetta VE, Davis RS, Pauls HW, Mason H, Choi-Sledeski YM, Green D, Cha D, Spada AP, Cheney DL, Mason JS, Maignan S, Guilloteau JP, Brown K, Colussi D, Bentley R, Bostwick J, Kasiewski CJ, Morgan SR, Leadley RJ, Dunwiddie CT, Perrone MH, Chu V.
    J Med Chem; 1999 Sep 09; 42(18):3557-71. PubMed ID: 10479288
    [Abstract] [Full Text] [Related]

  • 7. Halothiophene benzimidazoles as P1 surrogates of inhibitors of blood coagulation factor Xa.
    Mederski WW, Dorsch D, Anzali S, Gleitz J, Cezanne B, Tsaklakidis C.
    Bioorg Med Chem Lett; 2004 Jul 16; 14(14):3763-9. PubMed ID: 15203158
    [Abstract] [Full Text] [Related]

  • 8. Arylsulfonamidopiperidone derivatives as a novel class of factor Xa inhibitors.
    Shi Y, O'Connor SP, Sitkoff D, Zhang J, Shi M, Bisaha SN, Wang Y, Li C, Ruan Z, Lawrence RM, Klei HE, Kish K, Liu EC, Seiler SM, Schweizer L, Steinbacher TE, Schumacher WA, Robl JA, Macor JE, Atwal KS, Stein PD.
    Bioorg Med Chem Lett; 2011 Dec 15; 21(24):7516-21. PubMed ID: 22041058
    [Abstract] [Full Text] [Related]

  • 9. Design, synthesis, and biological evaluation of peptidomimetic inhibitors of factor XIa as novel anticoagulants.
    Lin J, Deng H, Jin L, Pandey P, Quinn J, Cantin S, Rynkiewicz MJ, Gorga JC, Bibbins F, Celatka CA, Nagafuji P, Bannister TD, Meyers HV, Babine RE, Hayward NJ, Weaver D, Benjamin H, Stassen F, Abdel-Meguid SS, Strickler JE.
    J Med Chem; 2006 Dec 28; 49(26):7781-91. PubMed ID: 17181160
    [Abstract] [Full Text] [Related]

  • 10. Orally active zwitterionic factor Xa inhibitors with long duration of action.
    Mochizuki A, Nagata T, Kanno H, Takano D, Kishida M, Suzuki M, Ohta T.
    Bioorg Med Chem Lett; 2011 Dec 15; 21(24):7337-43. PubMed ID: 22044620
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Design of benzamidine-type inhibitors of factor Xa.
    Gabriel B, Stubbs MT, Bergner A, Hauptmann J, Bode W, Stürzebecher J, Moroder L.
    J Med Chem; 1998 Oct 22; 41(22):4240-50. PubMed ID: 9784099
    [Abstract] [Full Text] [Related]

  • 13. Discovery of N-[2-[5-[Amino(imino)methyl]-2-hydroxyphenoxy]-3, 5-difluoro-6-[3-(4, 5-dihydro-1-methyl-1H-imidazol-2-yl)phenoxy]pyridin-4-yl]-N-methylgl y cine (ZK-807834): a potent, selective, and orally active inhibitor of the blood coagulation enzyme factor Xa.
    Phillips GB, Buckman BO, Davey DD, Eagen KA, Guilford WJ, Hinchman J, Ho E, Koovakkat S, Liang A, Light DR, Mohan R, Ng HP, Post JM, Shaw KJ, Smith D, Subramanyam B, Sullivan ME, Trinh L, Vergona R, Walters J, White K, Whitlow M, Wu S, Xu W, Morrissey MM.
    J Med Chem; 1998 Sep 10; 41(19):3557-62. PubMed ID: 9733480
    [No Abstract] [Full Text] [Related]

  • 14. Synthesis and structure-activity relationship of potent, selective and orally active anthranilamide-based factor Xa inhibitors: application of weakly basic sulfoximine group as novel S4 binding element.
    Pandya V, Jain M, Chakrabarti G, Soni H, Parmar B, Chaugule B, Patel J, Jarag T, Joshi J, Joshi N, Rath A, Unadkat V, Sharma B, Ajani H, Kumar J, Sairam KV, Patel H, Patel P.
    Eur J Med Chem; 2012 Dec 10; 58():136-52. PubMed ID: 23124211
    [Abstract] [Full Text] [Related]

  • 15. Cycloalkanediamine derivatives as novel blood coagulation factor Xa inhibitors.
    Nagata T, Yoshino T, Haginoya N, Yoshikawa K, Isobe Y, Furugohri T, Kanno H.
    Bioorg Med Chem Lett; 2007 Aug 15; 17(16):4683-8. PubMed ID: 17555959
    [Abstract] [Full Text] [Related]

  • 16. Synthesis and in vitro biological evaluation of aryl boronic acids as potential inhibitors of factor XIa.
    Lazarova TI, Jin L, Rynkiewicz M, Gorga JC, Bibbins F, Meyers HV, Babine R, Strickler J.
    Bioorg Med Chem Lett; 2006 Oct 01; 16(19):5022-7. PubMed ID: 16876411
    [Abstract] [Full Text] [Related]

  • 17. Design, synthesis and SAR of novel ethylenediamine and phenylenediamine derivatives as factor Xa inhibitors.
    Yoshikawa K, Yoshino T, Yokomizo Y, Uoto K, Naito H, Kawakami K, Mochizuki A, Nagata T, Suzuki M, Kanno H, Takemura M, Ohta T.
    Bioorg Med Chem Lett; 2011 Apr 01; 21(7):2133-40. PubMed ID: 21345673
    [Abstract] [Full Text] [Related]

  • 18. Synthesis and biological activity of novel 1,2-disubstituted benzene derivatives as factor Xa inhibitors.
    Koshio H, Hirayama F, Ishihara T, Shiraki R, Shigenaga T, Taniuchi Y, Sato K, Moritani Y, Iwatsuki Y, Kaku S, Katayama N, Kawasaki T, Matsumoto Y, Sakamoto S, Tsukamoto S.
    Bioorg Med Chem; 2005 Feb 15; 13(4):1305-23. PubMed ID: 15670939
    [Abstract] [Full Text] [Related]

  • 19. Aminobenzisoxazoles with biaryl P4 moieties as potent, selective, and orally bioavailable factor Xa inhibitors.
    Quan ML, Han Q, Fevig JM, Lam PY, Bai S, Knabb RM, Luettgen JM, Wong PC, Wexler RR.
    Bioorg Med Chem Lett; 2006 Apr 01; 16(7):1795-8. PubMed ID: 16434195
    [Abstract] [Full Text] [Related]

  • 20. Prodrug-based design, synthesis, and biological evaluation of N-benzenesulfonylpiperidine derivatives as novel, orally active factor Xa inhibitors.
    Ishihara T, Seki N, Hirayama F, Orita M, Koshio H, Taniuchi Y, Sakai-Moritani Y, Iwatsuki Y, Kaku S, Kawasaki T, Matsumoto Y, Tsukamoto S.
    Bioorg Med Chem; 2007 Jun 15; 15(12):4175-92. PubMed ID: 17416533
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.